Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Other Accumulated Expenses: 2015-2024

Historic Other Accumulated Expenses for Spyre Therapeutics (SYRE) over the last 10 years, with Dec 2024 value amounting to $501,000.

  • Spyre Therapeutics' Other Accumulated Expenses fell 67.68% to $170,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $170,000, marking a year-over-year decrease of 67.68%. This contributed to the annual value of $501,000 for FY2024, which is 2.66% up from last year.
  • Per Spyre Therapeutics' latest filing, its Other Accumulated Expenses stood at $501,000 for FY2024, which was up 2.66% from $488,000 recorded in FY2023.
  • Spyre Therapeutics' Other Accumulated Expenses' 5-year high stood at $783,000 during FY2021, with a 5-year trough of $330,000 in FY2022.
  • Over the past 3 years, Spyre Therapeutics' median Other Accumulated Expenses value was $488,000 (recorded in 2023), while the average stood at $439,667.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 68.75% in 2021, then slumped by 57.85% in 2022.
  • Spyre Therapeutics' Other Accumulated Expenses (Yearly) stood at $464,000 in 2020, then surged by 68.75% to $783,000 in 2021, then slumped by 57.85% to $330,000 in 2022, then spiked by 47.88% to $488,000 in 2023, then grew by 2.66% to $501,000 in 2024.